Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Biologic Accepts Smaller Stake in Qianfeng Acquisition

publication date: Dec 19, 2008

China Biologic Products, Inc. announced a number of changes to the agreement under which it will acquire a 90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd.  Dalin currently owns a 54% stake in Qianfeng Biological Products Co., Ltd. Like China Biologic, Qianfeng is a plasma-based biopharmaceutical company. While performing its due diligence, China Biologic found that Dalin owns only a 43.3% interest in Qianfeng instead of the 54% China Biologic originally bargained for. More details...

Stock Symbol: (OTCBB: CBPO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital